Allen C Gao
Affiliation: University of California
- Chandrasekar T, Yang J, Gao A, Evans C. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015;13:206 pubmed publisher..We review current knowledge of mechanisms of resistance to the currently approved treatments, development of adjunctive therapies, and identification of new pathways being targeted for therapeutic purposes. ..
- Armstrong C, Gao A. CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer. J Cell Commun Signal. 2017;11:89-91 pubmed publisher..The data from this manuscript highlight an intriguing potential therapeutic target for the treatment of CRPC and are a critical step forwards towards treating enzalutamide resistant prostate cancer. ..
- Liu C, Armstrong C, Lou W, Lombard A, Cucchiara V, Gu X, et al. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther. 2017;16:1521-1530 pubmed publisher..i>Mol Cancer Ther; 16(8); 1521-30. ©2017 AACR. ..
- Lombard A, Liu C, Armstrong C, Cucchiara V, Gu X, Lou W, et al. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer. Mol Cancer Ther. 2017;16:2257-2266 pubmed publisher..Furthermore, these preclinical studies suggest the potential in using combinations of antiandrogens with cabazitaxel for increased effect in treating advanced CRPC. Mol Cancer Ther; 16(10); 2257-66. ©2017 AACR. ..